^
Association details:
| Biomarker: | CD5 gene expression signature |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug Class: | BTK inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
CD5 Gene Signature Identifies Diffuse Large B-Cell Lymphomas Sensitive to Brutonʼs Tyrosine Kinase Inhibition
Published date:
12/11/2023
Excerpt:
Here, we developed a novel CD5 gene expression signature as a biomarker of response to BTKi-based therapy in DLBCL....CD5 expression was observed in 12% of non-GCB DLBCLs. CD5+ DLBCLs displayed transcriptional features of B-cell receptor (BCR) activation and were enriched for BCR-activating mutations known to correlate with BTKi sensitivity.
DOI:
10.1200/JCO.23.01574